Veryga turned to the Innovative Pharmaceutical Industry Association (IFPA), the American Chamber of Commerce’s Local American Working Group (LAWG) and the Association of Pharmaceutical Manufacturers, urging pharmaceutical companies in the associations to reduce the producer prices for Lithuania, so that they were under 95 percent of the average price of generic drugs in reference countries, the Ministry of Health said.
In its efforts to draft the price list of compensated drugs for 2017, the ministry said that declared prices of about 90 percent of the drugs were above the average.
“The draft price list shows that the declared prices for pharmaceuticals for Lithuania are much higher than in other reference countries for unknown reasons. Subsequently, patients are again forced to pay large surcharges for the medication. This should not be the case, as our country has definitely not yet used all the potential of bringing down prices for drugs. It is important to pursue the common goal together – ensure availability of the medication that Lithuanian patients need and make sure that the prices are as low as possible,” said Veryga.
Lithuania’s President Dalia Grybauskaitė recently said that medication compensation issues had been ignored, emphasizing that the issue was a test of confidence for the new health minister.